Emicizumab is a Monoclonal Antibody owned by Chugai Pharmaceutical, and is involved in 30 clinical trials, of which 12 were completed, 15 are ongoing, and 3 are planned.

Emicizumab (RG-6013) is a bi-specific antibody that mimics coagulation factor VIII. Hemophilia A is an inherited disorder, presenting severe bleeding symptoms repeated from childhood. In this disease, the blood coagulation reaction does not normally proceed because of congenital deficiency of factor VIII. Factor VIII simultaneously binds factor IXa and factor X to promote factor IXa-mediated factor X activation and the consequent blood coagulation reaction. Emicizumab binds to factor IXa and factor X, exerting factor VIII-mimetic function to promote the blood coagulation reaction under the factor VIII lacking condition regardless of the presence of inhibitors against factor VIII.

The revenue for Emicizumab is expected to reach a total of $89.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Emicizumab NPV Report.

Emicizumab is originated and owned by Chugai Pharmaceutical. F. Hoffmann-La Roche is the other company associated in development or marketing of Emicizumab.

Emicizumab Overview

Emicizumab (Hemlibra / RG-6013, ACE-910) is a humanized monoclonal modified immunoglobulin G4 (IgG4) bi-specific antibody acts as an anti-factor IXa- and anti-factor X or anti-haemophilic agent. It is formulated as injectable solution for subcutaneous route of administration. Hemlibra is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors, and also indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages, newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors. Hemlibra is indicated for the routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia A. 

Emicizumab is under development for the treatment of acquired mild to moderate hemophilia A and Von Willebrand Disease (vWD).

F. Hoffmann-La Roche Overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.

Quick View – Emicizumab

Report Segments
  • Innovator (NME)
Drug Name
  • Emicizumab
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Hematological Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.